3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Endocrine
1
Conditions
Breast Neoplasms
15
Neoplasm Metastasis
3
Hereditary Sensory and Autonomic Neuropathies
3
Squamous Cell Carcinoma of Head and Neck
2
Hyperglycemia
2
Advanced Breast Cancer
2
Vascular Malformations
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Skin Diseases, Vascular
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lymphatic Abnormalities
1
Lymphangioma, Cystic
1
Lymphangioma
1
Hormone Receptor Positive Breast Carcinoma
1
Head and Neck Neoplasms
1
Genetic Diseases, Inborn
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Exanthema
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Arteriovenous Malformations
1
Anatomic Stage III Breast Cancer AJCC v8
1
Adenocarcinoma of Lung
1
Interventions
Fulvestrant
2
Alpelisib
2
exemestane
1
dapagliflozin
1
Vildagliptin
1
Tamoxifen
1
Metformin
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Hyperglycemia
×
Alpelisib
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts